Capivasertib
- Generic Name
- Capivasertib
- Brand Names
- Truqap
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN6O2
- CAS Number
- 1143532-39-1
- Unique Ingredient Identifier
- WFR23M21IE
- Background
Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
- Conditions
- AdenocarcinomaNon-Small Cell Lung CancerCarcinoma, Squamous Cell
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 423
- Registration Number
- NCT02664935
- Locations
- 🇬🇧
Royal Devon and Exeter Hospital, Exeter, United Kingdom
🇬🇧University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
OLAParib COmbinations
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Joseph Paul Eder
- Target Recruit Count
- 67
- Registration Number
- NCT02576444
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 136
- Registration Number
- NCT02525068
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Conditions
- Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 124
- Registration Number
- NCT02523014
- Locations
- 🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial CarcinomaEsophageal CarcinomaExocrine Pancreas Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Cytology Specimen Collection ProcedureProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanProcedure: Echocardiography TestOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT02451956
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy
- Conditions
- Advanced Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2015-05-20
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02449655
- Locations
- 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of
PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 71
- Registration Number
- NCT02423603
- Locations
- 🇭🇺
University of Pécs - Clinical Center Institute of Oncotherapy, Pécs, Hungary
🇷🇴Center of Oncology Euroclinic, Iași, Romania
🇫🇷ICO René Gauducheau, Nantes, France
Trial of Olaparib in Combination With AZD5363 (ComPAKT)
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 60
- Registration Number
- NCT02338622
- Locations
- 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧Northern Institute for Cancer, Freeman Hospital, Newcastle, Newcastle upon Tyne, United Kingdom
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: AnthracyclinesDrug: TaxanesDrug: DNA intercalators
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 1460
- Registration Number
- NCT02299999
- Locations
- 🇫🇷
Hopitaux Universitaire de Strasbourg - Hopital Civil, Strasbourg, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷Hopitaux Du Leman, Thonon-les-Bains, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.